Sulfadoxine/pyrimethamine/moxifloxacin as an antimalarial drug: a study in plasmodium bergheiinfected mice
- Journal of Analytical & Pharmaceutical Research
Elias Adikwu,1 Igono Simeon Ajeka,2 Nwakaego Omonigho Ebong3
The use of triple antimalarial regimen may prevent Plasmodium parasites resistance. Moxifloxacin (M), a fluoroquinolone antibiotic has been associated with antiplasmodial activity. This study assessed the ability of M to increase the antiplasmodial activity of sulfadoxine/pyrimethamine (S/P) in mice infected with Plasmodium berghei. Adult Swiss albino mice (30-35g) of both sexes were randomly grouped and infected with Plasmodium berghei intraperitoneally. Curative, prophylactic and suppressive methods were followed and the mice were orally treated with S/P (21.4/10.7 mg/kg), M (6 mg/kg) and S/P/M, respectively. Chloroquine CQ (10mg/kg) served as the standard control. After treatment, blood samples were assessed for percentage parasitemia and hematological indices. Liver samples were evaluated for changes in histology. The mice were observed for mean survival time (MST).
Results: The curative, prophylactic and suppressive tests, showed decreased percentage parasitemia in mice treated with S/P/M with significance observed at p<0.05 when compared to S/P or M. In the curative test, 70.0 %, 67. 5% and 90.1% parasitemia inhibitions were produced by S/P, M and S/P/M respectively, whereas CQ produced 87.5 % inhibition. In the curative, prophylactic and suppressive tests, S/P/M prolonged MST with significant difference observed at p<0.05 when compared to S/P or M. S/P/M restored levels of hematological indices were characterized by significantly increased hemoglobin, packed cell volume, and red blood cells, with significantly decreased white blood cells at p<0.05 when compared to S/P or M. S/P/M eradicates liver Plasmodium parasite in treated mice. M increased the antiplasmodial activity of S/P. S/P/M may be used for malaria treatment.
sulfadoxine/pyrimethamine, moxifloxacin, malaria, plasmodium, mice